Cancer Lab · DeCure for X
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for familial ovarian carcinoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for familial ovarian carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
RAD51 paralog C (RAD51C) — RAD51C is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 8OUZ · 2.2 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
Ovarian carcinoma was diagnosed in seven women from one family, four of whom were sisters, and was suspected in three other relatives. This was the third reported familial aggregation of ovarian cancer with a pattern suggestive of transmission by a dominant gene or a polygenic mechanism. A separate family had four affected members in three consecutive generations, all with serous papillary adenocarcinoma, again consistent with a dominant mutant autosomal gene.
A Swedish nationwide study of 6,049 ovarian cancer patients from 1993 to 1999 found that patients with a family history had poorer survival than sporadic cases in both maternal and offspring generations. Among 80 mother-daughter pairs, there was a non-significant concordance of prognosis when survival was analysed according to the probands' length of survival. Histology was also a prognostic factor: women with borderline epithelial tumours had the best survival (hazard ratio 0.02 for cause-specific survival, 0.14 for overall survival), and good survival was also seen for sex cord-stromal tumours, germ cell tumours, and the clear cell, endometrioid, and mucinous cystadenocarcinoma subtypes of epithelial ovarian cancer.
In a retrospective study of 44 patients from a consecutive set of 62 treated for ovarian carcinoma in 1993, only two (4.55%) reported a first-degree relative with ovarian cancer. However, 13 patients (29.55%) reported a family history consistent with one of the hereditary ovarian cancer syndromes, showing early onset, bilaterality, multiple primary tumours, and transmission. All 13 patients in the hereditary group were Caucasian, which was the only significantly different demographic factor between the hereditary and sporadic groups.
What is still missing is prospective data on survival in families with known dominant gene mutations, a trial design that separates genetic subtypes rather than grouping all family history together, and patient stratification by histology and germline status to clarify whether the observed survival disadvantage is reproducible or confounded by ascertainment bias. No drug or treatment was mentioned in any of these abstracts.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractOvarian carcinoma was diagnosed in seven women, four of whom were sisters, and was suspected in three other relatives. To our knowledge, this is the third reported familial aggregation of ovarian cancer with a pattern suggestive of transmission by a dominant gene or a polygenic mechanism.
https://doi.org/10.1001/jama.1970.03180080139027AbstractINTRODUCTION: Earlier studies suggest that histology has no prognostic significance in patients with invasive ovarian tumors. Studies about the effect of family history on survival have given conflicting results, which we try to clarify in this study. As an additional question, we examined whether family members share survival experience. METHODS: We used the nation-wide Swedish Family-Cancer Database to estimate hazard ratios (HRs) for cause-specific and overall survival in ovarian cancer patients by histology and family history. HRs show the probability of death in the study group compared to the reference group. RESULTS: A total of 6,049 ovarian cancer patients with specific histologies were retrieved from our Database from years 1993 to 1999. Compared to women with epithelial ovarian cancer, women with borderline epithelial tumors had the best survival (HR 0.02 and 0.14 for cause-specific and overall survival). Good survival was also noted for patients with sex cord-stromal tumors and germ cell tumors. Among specific subtypes of epithelial ovarian cancers, good survival was noted for women with clear cell and endometrioid carcinomas and mucinous cystadenocarcinoma. The study covered 80 mother-daughter pairs with a family history. Patients with a family history had a poorer survival than sporadic cases in both maternal and offspring generations. When the survival was analyzed according to the probands' length of survival, there was a non-significant concordance of prognosis. CONCLUSION: Our data showed that histology and family history are prognostic factors for ovarian tumors. Patients with a family history had a more aggressive course than the sporadic cases.
https://doi.org/10.1080/02841860701784544AbstractFamilial aggregation of patients with ovarian carcinoma is unusual. A family with four affected members in three consecutive generations is described. The tumors were all of the serous papillary adenocarcinoma type. The pattern of appearance of the malignant disorder in the present family may be explained as the result of transmission of a dominant mutant autosomal gene. The future long term management of such a family might include prophylactic oophorectomy in certain family members, and possibly selective terminations of pregnancies with female fetuses in high-risk women.
https://doi.org/10.3109/03009737609179047AbstractIn order to determine the incidence of familial and hereditary ovarian cancer in a referral patient population, we conducted a retrospective study of 44 patients from a consecutive set of 62 patients treated for ovarian carcinoma at the Gynecologic Oncology Clinic at the Richland Memorial Hospital Center for Cancer Treatment and Research between January 1, 1993 and December 31, 1993. In our study of the referred patients, only two (4.55%) reported a history of at least one first-degree relative also being affected with ovarian cancer. However, 13 patients (29.55%) reported a family history consistent with one of the hereditary ovarian cancer syndromes. In addition to having a suggestive family history, these 13 families demonstrated several cardinal features of hereditary cancer syndromes including early onset, bilaterality, multiple primary tumors, and transmission. Race was the only significantly different demographic factor between the hereditary and sporadic ovarian cancer groups. All 13 patients who appeared to have a hereditary form of cancer were Caucasian.
https://doi.org/10.1007/bf01408663Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
